Medtronic’s ‘IN.PACT Admiral’ Drug-Eluting Balloon Edging Towards U.S. Market

Medtronic, Inc. tells us that that enough patients have been enrolled in its clinical studies of the IN.PACT Admiral drug-eluting balloon to support the company’s U.S. regulatory approval submission of the novel angioplasty device, which is designed to treat atherosclerotic lesions in the superficial femoral artery. The company plans to submit the first module of the pre-market approval (PMA) application for the IN.PACT Admiral drug-eluting balloon to the U.S. FDA over the summer.

Background

The Superficial Femoral Artery (SFA) experiences a variety of torsion and compression forces that pose inherent challenges with the use of permanent metallic stents in the treatment of atherosclerosis.

Medtronic’s IN.PACT drug-eluting balloons feature a proprietary coating called FreePac that is a formulation of paclitaxel and urea, an excipient that facilitates absorption of the drug into the vessel wall. They received the CE mark in 2008 and 2009 and are already available in many countries around the world.

More than 1,000 patients have been enrolled in the IN.PACT SFA I, II, II pharmacokinetics (PK) and Global studies to date. Clinical data from these studies will comprise a significant portion of Medtronic’s PMA application to the FDA for the IN.PACT Admiral drug-eluting balloon. IN.PACT SFA I is a European study with IN.PACT SFA II and II PK, both being U.S. studies. IN.PACT Global is an international study being conducted outside the United States.

The ongoing global IN.PACT clinical program includes 29 studies involving more than 4,600 patients at approximately 230 sites worldwide. Through these company-sponsored and physician-initiated studies, Medtronic’s portfolio of IN.PACT drug-eluting balloons will be investigated thoroughly for the treatment of arterial disease in a variety of vessel beds. As part of this program, Medtronic is currently enrolling the IN.PACT Global study, a first-of-its-kind, “real-world” evaluation of the company’s IN.PACT drug-eluting balloons involving 1,500 patients with femoropopliteal lesions of any length at up to 80 sites worldwide.

Company comments 

“The IN.PACT Admiral drug-eluting balloon represents a novel angioplasty device from Medtronic that we foresee launching in the United States in late 2015, pending FDA approval,” said Tony Semedo, president of Medtronic’s Endovascular Therapies business. “It targets atherosclerotic lesions in the superficial femoral artery with a treatment modality that aims to deliver an anti-restenotic drug while leaving nothing behind.”

Regulatory status

In the United States, the IN.PACT Admiral drug-eluting balloon is limited to investigational use under an investigational device exemption  granted by the FDA and, like every drug-eluting balloon, is not yet commercially available.

Source: Medtronic, Inc.